top of page

Revolutionizing Weight Loss: 5 things to know about Semaglutide vs. Tirzepatide

Updated: Dec 28, 2023

"Revolutionizing Weight Loss: 5 things to know about Semaglutide vs. Tirzepatide"


Obesity is a prevalent health concern worldwide, contributing to various medical conditions such as cardiovascular diseases, diabetes, and even certain cancers.

At DB2 we know managing weight effectively is crucial for overall health and well-being. Semaglutide and Tirzepatide have emerged as breakthrough medications offering promising results in weight management.



 1. Understanding Semaglutide

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, acts on the hypothalamus to reduce appetite and food intake while increasing feelings of fullness. In clinical trials like the STEP trials, Semaglutide has demonstrated substantial weight loss results, with participants achieving an average weight reduction of 15.8kg or 34.7lbs over 68 weeks. The FDA-approved dose for weight loss is .25mg – 2.4mg once weekly through subcutaneous injection. However, some potential side effects like nausea, vomiting, and diarrhea might occur, particularly during initial usage.

 

2. Exploring Tirzepatide

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, targeting multiple pathways involved in glucose and weight regulation. Studies, including SURPASS trials, have shown Tirzepatide's effectiveness, yielding total mean weight loss of 26.6% (29.2 kg or 64.4 lb.) from study entry over 84 weeks. Participants on placebo achieved a total mean weight loss of 3.8% (4.1 kg or 9.0 lb.) from study entry over 84 weeks. The FDA-approved dosing regimen for weight management is 2.5 mg – 15mg, administered weekly via subcutaneous injection. Side effects may include gastrointestinal disturbances, although generally, they tend to diminish over time.


 3. Efficacy and Safety

Comparing both medications, Semaglutide and Tirzepatide, demonstrates similar efficacy in promoting weight loss. However, individual responses may vary. Regarding safety, both medications have shown generally well-tolerated profiles, with gastrointestinal side effects being the most common. Semaglutide might have a slightly higher incidence of nausea during the initial phase compared to Tirzepatide. Despite the safety of these medications DB2 stresses the importance of being evaluated by a medical professional and seeking medical supervision on your weight loss journey.


 4. Patient Considerations and Recommendations

At DB2 our providers consider various factors when prescribing Semaglutide or Tirzepatide, including a patient's medical history, existing conditions, and potential drug interactions. Patients must be educated about the benefits and potential side effects of these medications. Including, the cost, availability and administration by injection. Additionally, it's vital to emphasize the role of lifestyle modifications, exercise, and a balanced diet alongside medication for optimal weight management. If you are confused about engaging a trainer, nutritional expert or a health coach…DB2 has connections for you.


 5. Future Directions and Conclusion

Ongoing research continues to explore the long-term effects, safety, and potential combination therapies involving Semaglutide, Tirzepatide and other weight loss treatments. These medications offer hope for individuals struggling with obesity, but their use should be a part of a comprehensive medically managed weight loss plan. DB2s Doctor and Medical team are dedicated to helping you transform your life and restore your hope for a better quality of life. Consulting a healthcare professional is crucial before starting any new medication regimen. Call DB2 Regeneration Clinic today 636 265-2822 or book a appointment on line at DB2regeneration.com

 


New Years resolutions of weight loss. Get an Understanding about Semaglutide vs Tirzepatide.
DB2 Regeneration guides you through the weight loss journey.

References:

1.    Davies M. J., Bergenstal R., Bode B., Kushner R. F., Lewin A., Skjøth T. V., Andreasen A. H., Jensen C. B., DeFronzo R. A. (2017). Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA, 314(7), 687–699. DOI: 10.1001/jama.2015.9676

2.    FDA. (2021). Highlights of Prescribing Information: Semaglutide for chronic weight management. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213051s000lbl.pdf

3.    EMA. (2022). Summary of Product Characteristics: Tirzepatide for the treatment of obesity. https://www.ema.europa.eu/en/documents/product-information/tyzepi-epar-product-information_en.pdf

167 views0 comments

Comments


bottom of page